119-hr2343

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2343 Introduced in House

    (IH) ]

<DOC>

119th CONGRESS
 1st Session
 H. R. 2343

To amend title XVIII of the Social Security Act to provide for coverage 
and payment of Alpha-1 Antitrypsin Deficiency Disorder treatment under 
 part B of such title, and for other purposes.

_______________________________________________________________________

 IN THE HOUSE OF REPRESENTATIVES

 March 25, 2025

 Ms. Salazar (for herself, Ms. Pingree, Mr. Smith of New Jersey, Mr. 
 Johnson of Georgia, Mr. Owens, Ms. Norton, Mrs. Kim, Mr. Rouzer, and 
 Mr. Tonko) introduced the following bill; which was referred to the 
 Committee on Energy and Commerce, and in addition to the Committee on 
 Ways and Means, for a period to be subsequently determined by the 
 Speaker, in each case for consideration of such provisions as fall 
 within the jurisdiction of the committee concerned

_______________________________________________________________________

 A BILL

To amend title XVIII of the Social Security Act to provide for coverage 
and payment of Alpha-1 Antitrypsin Deficiency Disorder treatment under 
 part B of such title, and for other purposes.

 Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

 This Act may be cited as the ``John W. Walsh Alpha-1 Home Infusion 
Act of 2025''.

SEC. 2. MEDICARE COVERAGE OF ALPHA-1 ANTITRYPSIN DISORDER TREATMENT.

    (a) In General.--

Section 1861 of the Social Security Act (42 U.S.C. 
1395x) is amended--

    (1) in subsection

    (s)

    (2) --
        (A) by striking ``and'' at the end of subparagraph
            (II) ;
        (B) by inserting ``and'' at the end of subparagraph

    (JJ) ; and
            (C) by inserting at the end the following new 
 subparagraph:
 ``

    (KK) Alpha-1 Antitrypsin Deficiency Disorder 
 treatment (as defined in subsection

    (nnn) );''; and

    (2) by adding at the end the following new subsection:
 ``

    (nnn) Alpha-1 Antitrypsin Deficiency Disorder Treatment.--

    (1) The 
term `Alpha-1 Antitrypsin Deficiency Disorder treatment' means 
augmentation therapy (as defined in paragraph

    (2)
            (C) ) furnished by 
qualified home infusion therapy suppliers (as defined in paragraph

    (2)
            (D) ) which are furnished in the individual's home (as defined in 
paragraph

    (2)
        (B) ) to an individual--
 ``
        (A) who is under the care of an applicable provider;
 ``
        (B) who is enrolled under both parts A and B of this 
 title, and is not enrolled in an MA plan under part C of such 
 title; and
 ``
            (C) who requires augmentation therapy (as defined in 
 paragraph

    (2)
            (C) ).
 ``

    (2) For purposes of this subsection:
 ``
        (A) The term `applicable provider' means--
 ``
            (i) a physician;
 ``
            (ii) a nurse practitioner; and
 ``
            (iii) a physician assistant.
 ``
        (B) The term `home' means a place of residence used as 
 the home of an individual (as defined for purposes of 
 subsection

    (n) ).
 ``
            (C) The term `augmentation therapy' means an Alpha-1 
 Proteinase Inhibitor indicated for chronic augmentation and 
 maintenance therapy in adults with clinical evidence of 
 emphysema due to severe hereditary deficiency of Alpha-1 
 Antitrypsin.
 ``
            (D) The term `qualified home infusion therapy supplier' 
 has the meaning given such term in subsection
            (iii) (3)
            (D) 
            (i) .''.

    (b) Payment for Intravenous Administration Kits and Nursing 
Services for Alpha-1 Antitrypsin Deficiency Disorder Treatment.--

Section 1834 of the Social Security Act (42 U.S.C. 1395m) is amended by 
adding at the end the following new subsection:
 ``

    (aa) Payment for Intravenous Administration Kits and Nursing 
Services for Alpha-1 Antitrypsin Deficiency Disorder Treatment.--The 
Secretary shall implement a payment system under which payment is made 
under this title to a qualified home infusion therapy supplier (as 
defined in 

section 1861

    (nnn)

    (3)
            (D) ) for intravenous administration kits 
and nursing services for up to 2 hours of care by a qualified home 
infusion therapy supplier in coordination with the furnishing of 
augmentation therapy (as defined in 

section 1861

    (nnn)

    (2)
            (C) ).''.
            (c) Conforming Amendments.--

    (1) Payment reference.--

Section 1833

    (a)

    (1) of the Social 
 Security Act (42 U.S.C. 1395l

    (a)

    (1) ) is amended--
        (A) by striking ``and'' before ``

    (HH) ''; and
        (B) by inserting before the semicolon at the end 
 the following: ``, and
            (II) with respect to intravenous 
 administration kits and nursing services described in 
 

section 1834

    (aa) for Alpha-1 Antitrypsin Disorder 
 treatment (as defined in subsection

    (nnn)

    (1) ), the 
 amount paid for such kits and services shall be an 
 amount equal to 80 percent of the lesser of the actual 
 charge for the services or the amount determined under 
 

section 1834

    (aa) ''.

    (2) Direct payment.--The first sentence of 

section 1842

    (b)

    (6) of the Social Security Act (42 U.S.C. 1395u

    (b)

    (6) ) 
 is amended--
        (A) by striking ``and'' before ``
        (J) ''; and
        (B) by inserting before the period at the end the 
 following: ``, and
        (K) in the case of intravenous 
 administration kits and nursing services described in 
 

section 1834

    (aa) , payment shall be made to the 
 qualified home infusion therapy supplier (as defined in 
 

section 1861

    (nnn)

    (2)
            (D) )''.

    (3) Exclusion from home health services.--

Section 1861
            (m) of the Social Security Act (42 U.S.C. 1395x
            (m) ) is amended, in 
 the first sentence, by inserting the following before the 
 period at the end: ``and intravenous administration kits and 
 nursing services described in 

section 1834

    (aa) for Alpha-1 
 Antitrypsin Deficiency Disorder treatment (as defined in 
 subsection

    (nnn)

    (1) )''.
            (d) Effective Date.--The amendments made by this section shall 
apply to items and services furnished on or after January 1, 2027.
 <all>